The Hunt for the Next 10 Bagger

[Covid19freak]

FBIO $1.35 -MC $15 m -FDA Decision on January 3 (cancer treatment) and NDA submission for rosacea treatment expected before year end .super cheap low floater with nice upside

https://finance.yahoo.com/news/fortress-biotech-reports-third-quarter-211000362.html

We’re looking forward to multiple significant near-term milestones, including potentially up to four New Drug Application (“NDA”) and Biologics License Application (“BLA”) submissions to the U.S. Food and Drug Administration (“FDA”) between 2023 and 2025, one of which is a NDA for DFD-29 to treat rosacea around the end of this year. We are also anticipating the PDUFA goal date of January 3, 2024, for cosibelimab, our investigational anti-PD-L1 antibody, as a treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (“cSCC”).”